Rapid eye movement (REM) sleep behavior disorder (RBD) is parasomnia characterized by REM sleep without atonia (RWA) and elaborate motor activity in association with dream mentation. Periodic leg movement during sleep (PLMS) is observed in a large share of patients with RBD, suggesting a common pathology: dopaminergic dysfunction. This study was undertaken to evaluate the effectiveness and mechanism of action of pramipexole, a dopamine agonist, on RBD symptoms. Fifteen patients (57-75 years old) with RBD with a PLMS index of more than 15 events/h shown by nocturnal polysomnography were enrolled. Sleep variables, the score of severity for RBD symptoms, REM density, and PLM index were compared before and after one month or more of consecutive pramipexole treatment. Correlation analysis was conducted between the rate of change in RBD symptoms and the rate of reduction of REM density. Fourteen patients with RBD (80.0%) achieved symptomatic improvement of RBD with pramipexole treatment, which reduced REM density and PLM index during non-REM sleep despite the unchanged amount of RWA. The rate of change in RBD symptoms correlated positively with the rate of REM density reduction. Significant reduction of the PLM index was observed in non-REM sleep but not in REM sleep. Periodic leg movement during sleep (PLMS) is often comorbid with RBD, suggesting a common pathogenesis of the two disorders. Its frequency in RBD is higher than that seen in the normal population, especially during the REM sleep period (Fantini et al. 2002) . Although two previous case series investigated the effectiveness of pramipexole on RBD symptoms (Fantini et al. 2003; Schmidt et al. 2006 ), these studies did not respectively examine the effect of pramipexole on PLMS during non-REM (NREM) and REM sleep periods. Moreover, the pathophysiology of PLMS in idiopathic RBD remains unsolved.
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by dream-enacting behavior associated with REM sleep without atonia (RWA). Although the pathogenesis of RBD remains unclear, RBD is frequently associated with α-synucleinopathies including Parkinson disease (PD), dementia with Lewy bodies, and multiple system atrophy. It has been widely accepted that RBD represents a prodromal phase of these diseases (Olson et al. 2000; Boeve and Saper 2006; Iranzo et al. 2006; Postuma et al. 2006) .
Periodic leg movement during sleep (PLMS) is often comorbid with RBD, suggesting a common pathogenesis of the two disorders. Its frequency in RBD is higher than that seen in the normal population, especially during the REM sleep period (Fantini et al. 2002) . Although two previous case series investigated the effectiveness of pramipexole on RBD symptoms (Fantini et al. 2003; Schmidt et al. 2006) , these studies did not respectively examine the effect of pramipexole on PLMS during non-REM (NREM) and REM sleep periods. Moreover, the pathophysiology of PLMS in idiopathic RBD remains unsolved.
Episodes of violent behavior in RBD are mostly associated with nightmares. However, no report describes the effectiveness of pramipexole for alleviating nightmares in RBD or its relation to REM density, which possibly triggers dream imagery (Ogawa et al. 2005) .
To elucidate the mechanism of pramipexole action on the pathogenesis of RBD, we investigated its effects on RBD symptoms, with particular attention to REM-related parameters and PLMS in this pilot study. (AASM 2005) and who showed a PLMS index of more than 15 events/h on nocturnal polysomnography (n-PSG), were enrolled in this study. All patients had no other sleep disorder or symptom suggestive of neurodegenerative disorder and/or dementia. After diagnosis with PSGs and clinical interviews, the patients began treatment with pramipexole and underwent a second n-PSG more than 3 months after starting the treatment. All the patient subjects were drug naïve before starting the treatment for RBD. All patients who had taken any concomitant treatments other than pramipexole were excluded from this study.
Methods

Subjects
PSG variables
Sleep stages were scored according to criteria set by Rechtschaffen and Kales. The RWA and REM density were scored according to a previously described method (Consens et al. 2005) . REM density was defined as the ratio of the number of 3-s epochs of REM sleep with at least 1 REM divided by the total number of all 3-s epochs with REM sleep. The reduction rate of REM density with the treatment was calculated by dividing the difference in the REM densities measured before and after medication by the value of REM density before medication. The severity of RBD symptoms was assessed according to criteria explained in the revised edition of ICSD-1 (AASM 2001) based on reports of the frequency and intensity of vocalization or dream enactment behavior obtained from patients or their family members. Additionally, we assessed the subjective frequency of nightmares based on their reports. The rate of reduction of RBD symptoms was calculated by taking the difference in the scores of RBD symptoms obtained before and after medication and dividing that difference by the score before medication. PLMS was scored according to the criteria set by AASM (AASM 2007) . PLMS was distinguished carefully from phasic EMG activity on the anterior tibialis muscle during stage REM by consideration of the periodicity or amplitude of leg movements.
Statistical analysis
Using Wilcoxon signed rank tests, scores of RBD symptoms and sleep variables before and after treatment were compared. Correlation between the rate of change of the RBD symptoms and the rate of reduction of REM density was investigated using Spearman's rank correlation coefficient.
Results
Kolmogorov-Smirnov tests revealed that the sleep variables were not normally distributed. Table 1 shows that the mean dosage of pramipexole was 0.21 ± 0.09 mg/day. The mean duration of the treatment before the second n-PSG was 9.1 ± 7.1 months. Subjective assessment revealed that 12 patients (80%) achieved clear improvement with the pramipexole treatment: 50% reduction in the score for severity of RBD symptoms. The scores of severity for RBD symptoms after pramipexole treatment were significantly lower than those before the treatment (Z = −3.376, 66.5 ± 5.2 M:F = 8:7 0.2 ± 0.1 8.0 ± 7.0 2.8 ± 0.4 1.1 ± 0.6* RBD, REM sleep behavior disorder. *p < 0.01 compared to the score of severity of RBD symptoms before treatment. 1) Severity of RBD symptoms are scored for 0 = none; 1 = REM sleep behavior occurs less than once per month and causes only mild discomfort for the patient or bed-partner, 2 = REM sleep behavior occurs more than once per month but less than once per week and is usually associated with physical discomfort to the patient or bed-partner, 3 = REM sleep behavior occurs more than once per week and is associated with physical injury to the patient or bed-partner.
2) Improvement of nightmares means 50% or more reduction of frequency of nightmare.
p < 0.01). All the patient subjects complained of frequent nightmares before treatment. After pramipexole treatment, five patients (33.3%) reported complete disappearance of nightmares, the number of patients having nightmares decreased to six patients (40.0%). Consequently, among the 12 patients who achieved clear improvement of RBD symptoms, 10 patients (83.3%) reported disappearance or improvement of nightmares.
Regarding n-PSG measures, no significant differences in the sleep stage variables, including the amount of RWA, were found between those assessed before and after treatment with pramipexole. However, the REM density after the treatment was significantly lower than the value before the treatment (Z = −2.556, p < 0.01). Among PLMS measures, the PLMS index during the sleep period as a whole (Z = −3.238, p < 0.01), the index during NREM sleep period (Z = −3.351, p < 0.01), and the PLMS arousal index (Z = −3.297, p < 0.01) decreased significantly after the treatment. Nevertheless, no significant change in PLMS index was observed during the REM sleep period (Table 2) .
Regarding the relation between the RBD symptoms and the REM density, positive correlation was found between the reduction rate of RBD symptoms and that of REM density with pramipexole treatment (rs = 0.785, p < 0.01) (Fig. 1) .
Discussion
According to a recent review of the effectiveness of interventions in RBD (Aurora et al. 2010) , only two reports have described published studies that evaluated the effectiveness of pramipexole treatment on idiopathic RBD (Fantini et al. 2003; Schmidt et al. 2006) . Fantini et al. (2003) reported that 7 of 8 patients reported reduced RBD clinical manifestations after pramipexole treatment. Schmidt et al. (2006) also reported that pramipexole mitigated the RBD symptom severity. However, to date, the mechanism of action of pramipexole on RBD symptoms remains unclear.
This study is the first to investigate the influence of pramipexole on RBD symptoms, PLMS-related variables, and REM-related PSG variables simultaneously. The results of our study show that pramipexole treatment improved RBD symptoms in 80.0% patients, suggesting that pramipexole is effective for the treatment of idiopathic RBD. Fantini et al. (2003) reported that pramipexole treatment decreased neither the amount of phasic EMG activity nor the REM density. Consistent with their finding, the amount of RWA did not decrease in this study. Zhang et al. (2008) reported that RBD episodes do not occur commonly during one-night PSG monitoring and reported that the occurrence tends to show high night-to-night variation. In the present study, however, RBD symptoms examined before and after treatment were evaluated according to reports about RBD symptoms obtained from the patients or their family members. The severity was rated according to the revised edition of ICSD-1. Therefore, the improvement of RBD symptoms after treatment was not explained by the night-to-night variation of the occurrence of RBD episodes. Regarding EMG activity, Zhang et al. reported high correlations in both tonic and phasic EMG activities between night 1 and night 2 (tonic, r = 0.82; phasic, r = 0.83). Accordingly, no difference in the amount of RWA between those measured before and after treatment was thought to depend on the night-to-night variation of the amount of RWA; pramipexole cannot influence RWA.
Inconsistent with Fantini's report, a significant decrease in REM density after treatment with pramipexole was observed in this study. The reason for the inconsistency in REM density findings remains unknown. Nevertheless, it is noteworthy that in the present study, the changes in RBD symptoms with pramipexole treatment were associated significantly with the reduction of REM density. This study lacked data related to comparison between RBD patients and the control group. However, Tachibana et al. reported previously that RBD patients showed a significantly higher REM density than that of control subjects (Tachibana et al. 1994) . Reportedly, neural activity in the parieto-occipital visual cortex after the appearance of REMs during the REM sleep period can trigger dream imagery (Ogawa et al. 2005; Miyauchi et al. 2009 ). Based on these earlier reports and the results of the present study, the improvement in RBD symptoms associated with the reduction of REM density indicates that the effectiveness of pramipexole on RBD symptoms depends on a decrease in the vividness or the number of dreams linked closely with REM density. This idea is supported by the fact that 83.3% of patients with clear improvement of RBD symptoms showed the reduction or disappearance of nightmares after pramipexole treatment.
High doses of dopaminergic drugs are known to induce vivid dreams, nightmares, and RBD in PD patients (Kulisevsky and Roldan 2004; Gjerstad et al. 2008) . In contrast, consistent with previous studies (Fantini et al. 2003; Schmidt et al. 2006) , the results of our study suggest that a low dose of pramipexole can be effective for reducing nightmares, engendering improvement in RBD symptoms in patients with idiopathic RBD. In this regard, the effect of pramipexole on idiopathic RBD might differ from that on secondary RBD in PD patients who are already taking high-dosage dopaminergic medication (Kumru et al. 2008) . Effects of pramipexole might differ depending on differences in the dosage of dopaminergic medication or in the presence or absence of neurodegenerative disorders (Aurora et al. 2010 ). Further study is necessary to clarify this issue.
It remains unclear whether dopaminergic dysregulation is involved in PLMS in RBD. Fantini et al. (2003) reported no change in the PLMS index in patients with RBD after pramipexole treatment. However, no report in the relevant literature describes the influence of pramipexole on PLMS in RBD during NREM and REM sleep periods. The results of the present study demonstrated that selective improvement of PLMS during NREM sleep period occurs in patients with idiopathic RBD. Bliwise and Rye (2008) reported that, in comparison with healthy controls, higher EMG activity detected by the phasic electromyographic metric (PEM) rate was observed in patients with RBD, especially during REM sleep. In addition, Huang et al. (2011) reported that excessive electromyographic activities in RBD patients might ameliorate the severity of OSA, especially during REM sleep, possibly because of activation of upper airway dilator muscles. These increased muscle activities during REM sleep might also be associated with the increased PLMS and its weak responsiveness to pramipexole treatment during REM sleep in RBD patients. Consequently, the difference in the effectiveness of pramipexole treatment might indicate that PLMS during REM sleep period has a pathology associated with a lack of REM sleep motor inhibition probably because of brainstem dysfunction (Fantini et al. 2002) rather than dopaminergic dysfunction. However, this study presents some limitations. First, this study was not a randomized controlled investigation. Second, the participating subjects were enrolled from one institute and the number of study subjects was small. A future double-blind placebo-controlled trial of pramipexole treatment on numerous RBD patients is desirable for confirming our results. Third, the evaluation of RBD symptom severity was made according to the criteria set in the revised edition of ICSD-1. More comprehensive rating scales for RBD severity that have been published more recently must be used to evaluate RBD symptoms (Boeve et al. 2007; Stiasny-Kolster et al. 2007; Li et al. 2010 ).
This study shows that treatment with pramipexole improves RBD symptoms, possibly via a mechanism involving a reduction in the REM density. Pramipexole decreases PLMS only during the NREM sleep period, suggesting that other factors affect the pathophysiology of PLMS during the REM sleep period in RBD. Additional double-blind, randomized, controlled trials must be conducted to provide new insights into the effectiveness and mechanism of action of pramipexole on idiopathic RBD.
